| # | Title | Journal | Year | Citations |
|---|
| 1 | Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | Lancet, The | 2013 | 2,094 |
| 2 | Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis | Lancet, The | 2018 | 2,076 |
| 3 | Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care | World Psychiatry | 2011 | 1,767 |
| 4 | Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis | Lancet, The | 2009 | 1,663 |
| 5 | Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis | Lancet, The | 2019 | 1,050 |
| 6 | Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis | Lancet, The | 2012 | 742 |
| 7 | New insights into the genetic etiology of Alzheimer’s disease and related dementias | Nature Genetics | 2022 | 700 |
| 8 | Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level | World Psychiatry | 2011 | 631 |
| 9 | Mapping Scores Onto Stages: Mini-Mental State Examination and Clinical Dementia Rating | American Journal of Geriatric Psychiatry | 2006 | 564 |
| 10 | Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis | Lancet, The | 2016 | 513 |
| 11 | Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study | European Journal of Nuclear Medicine and Molecular Imaging | 2003 | 510 |
| 12 | Prevalence of Amyloid PET Positivity in Dementia Syndromes | JAMA - Journal of the American Medical Association | 2015 | 501 |
| 13 | A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia | American Journal of Psychiatry | 2009 | 453 |
| 14 | How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials | Molecular Psychiatry | 2009 | 428 |
| 15 | Dose Equivalents for Antipsychotic Drugs: The DDD Method: Table 1. | Schizophrenia Bulletin | 2016 | 428 |
| 16 | Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial | British Journal of Psychiatry | 2010 | 364 |
| 17 | Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses | British Journal of Psychiatry | 2012 | 332 |
| 18 | η-Secretase processing of APP inhibits neuronal activity in the hippocampus | Nature | 2015 | 308 |
| 19 | Frontotemporal dementia and its subtypes: a genome-wide association study | Lancet Neurology, The | 2014 | 302 |
| 20 | Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes | Journal of Psychopharmacology | 2008 | 288 |
| 21 | Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update | Schizophrenia Bulletin | 2014 | 288 |
| 22 | Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis | Lancet Psychiatry,the | 2014 | 280 |
| 23 | Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method | Schizophrenia Bulletin | 2014 | 277 |
| 24 | Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials | Journal of Affective Disorders | 2015 | 267 |
| 25 | Chronic Kidney Disease and Cognitive Impairment: A Systematic Review and Meta-Analysis | American Journal of Nephrology | 2012 | 251 |
| 26 | A Pan‐European Study of theC9orf72Repeat Associated withFTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats | Human Mutation | 2013 | 247 |
| 27 | Efficacy of Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders | JAMA Psychiatry | 2014 | 244 |
| 28 | Cognitive impairment in 873 patients with idiopathic Parkinson's disease | Journal of Neurology | 2008 | 242 |
| 29 | Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load | Journal of Neurochemistry | 2007 | 237 |
| 30 | Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia | JAMA Psychiatry | 2016 | 235 |
| 31 | Shared decision making in psychiatry | Acta Psychiatrica Scandinavica | 2003 | 233 |
| 32 | Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials | Neuropsychopharmacology | 2011 | 222 |
| 33 | Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease | Journal of Neurology | 2010 | 216 |
| 34 | Second‐generation antipsychotic effect on cognition in patients with schizophrenia—a meta‐analysis of randomized clinical trials | Acta Psychiatrica Scandinavica | 2015 | 216 |
| 35 | Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment | Archives of Neurology | 2002 | 214 |
| 36 | Physical Activity and Incident Cognitive Impairment in Elderly Persons | Archives of Internal Medicine | 2010 | 211 |
| 37 | Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias | Molecular Psychiatry | 2003 | 209 |
| 38 | Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome | International Journal of Geriatric Psychiatry | 2006 | 198 |
| 39 | Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study | Neurobiology of Aging | 2007 | 194 |
| 40 | Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis | Lancet Psychiatry,the | 2019 | 184 |
| 41 | Neuronal hyperactivity – A key defect in Alzheimer's disease? | BioEssays | 2015 | 182 |
| 42 | Rescue of long-range circuit dysfunction in Alzheimer's disease models | Nature Neuroscience | 2015 | 179 |
| 43 | Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis | Lancet Psychiatry,the | 2020 | 176 |
| 44 | Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration | Neurology | 2002 | 171 |
| 45 | Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs | Neuropsychopharmacology | 2007 | 171 |
| 46 | Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment | Journal of Alzheimer's Disease | 2019 | 171 |
| 47 | Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis | American Journal of Psychiatry | 2016 | 167 |
| 48 | Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies | Lancet Psychiatry,the | 2016 | 161 |
| 49 | Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders | Brain | 2020 | 158 |
| 50 | Cognitive rehabilitation in patients with mild cognitive impairment | International Journal of Geriatric Psychiatry | 2009 | 157 |
